Table 5 Distribution of examined markers according to subtypes
Luminal A | Luminal B | Luminal-HER2 | HER2-enriched | TNBC | BCP | |
|---|---|---|---|---|---|---|
N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
alphaB-crystallin | ||||||
Negative | 213 (93.4) | 299 (80.6) | 109 (83.8) | 88 (88.0) | 61 (55.0) | 41 (48.2) |
Weakly positive | 8 (3.5) | 40 (10.8) | 16 (12.3) | 11 (11.0) | 24 (21.6) | 19 (22.4) |
Strongly positive | 7 (3.1) | 32 (8.6) | 5 (3.8) | 1 (1.0) | 26 (23.4) | 25 (29.4) |
BRCA1 | ||||||
Negative | 206 (92.0) | 334 (91.0) | 125 (97.7) | 95 (95.0) | 103 (94.5) | 79 (92.9) |
Positive | 18 (8.0) | 33 (9.0) | 3 (2.3) | 5 (5.0) | 6 (5.5) | 6 (7.1) |
BRCA1 | ||||||
WT | 19 (90.5) | 27 (100.0) | 11 (100.0) | 10 (100.0) | 11 (64.7) | 9 (60.0) |
Mutated | 2 (9.5) | 0 | 0 | 0 | 6 (35.3) | 6 (40.0) |
p53 | ||||||
Negative | 148 (67.3) | 154 (42.1) | 56 (43.8) | 41 (42.3) | 46 (43.0) | 32 (38.6) |
Positive | 72 (32.7) | 212 (57.9) | 72 (56.3) | 56 (57.7) | 61 (57.0) | 51 (61.4) |